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Abstract 
Context 
Oncostatin M (OSM) plays a key role in inflammation, but its regulation and function during obesity 
is not fully understood. 
Objective 
The aim of this study was to evaluate the relationship of OSM with the inflammatory state that leads 
to impaired glucose homeostasis in obesity. We also assessed whether OSM immunoneutralization 
could revert metabolic disturbances caused by a high-fat diet (HFD) in mice. 
Design 
28 patients with severe obesity were included and stratified into two groups:  1) glucose levels < 100 
mg/dL and 2) glucose levels > 100 mg/dL. White adipose tissue was obtained to examine OSM gene 
expression. Human adipocytes were used to evaluate the effect of OSM in the inflammatory response, 
and HFD-fed C57BL/6J mice were injected with anti-OSM antibody to evaluate its effects. 
Results 
OSM expression was elevated in subcutaneous and visceral fat from patients with obesity and 
hyperglycemia, and correlated with Glut4 mRNA levels, serum insulin, HOMA-IR, and 
inflammatory markers. OSM inhibited adipogenesis and induced inflammation in human adipocytes. 
Finally, OSM receptor knockout mice had increased Glut4 mRNA levels in adipose tissue, and OSM 
immunoneutralization resulted in a reduction of glucose levels and Ccl2 expression in adipose tissue 
from HFD-fed mice. 
Conclusions 
OSM contributes to the inflammatory state during obesity and may be involved in the development 
of insulin resistance. 
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Introduction 
Obesity has reached epidemic proportions worldwide, and its prevalence has doubled in the 
last 30 years. The prevalence of obesity affects more than 25% of the population, whereas a 
remarkable 60% of the population is overweight. Moreover, it has been estimated that approximately 
350 million people have diabetes, representing almost 10% of the global  population (1). White 
adipose tissue (WAT) is a crucial regulator of energy balance and glucose homeostasis, owing to its 
function as a lipid-storing and endocrine organ. Obesity is characterized by chronic, low-grade 
adipose tissue inflammation accompanied by an increased presence of various pro-inflammatory 
immune cells, including macrophages (2). The first wave of macrophage accumulation in WAT 
during the early phase of obesity is essential for healthy expansion and remodeling of adipose tissue 
(3). However, chronic infiltration of adipose tissue by macrophages, their polarization from a M2 
anti-inflammatory state to a M1-like inflammatory state, and increased expression and secretion of 
pro-inflammatory cytokines have been shown to negatively impact systemic glucose homeostasis (4-
7). Moreover, inflammatory processes may affect the browning capacity of WAT and by this means 
may also contribute to obesity‐associated metabolic disease. Indeed, it has been demonstrated that 
the immune cell infiltration of subcutaneous WAT creates a deleterious inflammatory 
microenvironment that impairs the capacity of precursor cells to differentiate into thermogenically-
active beige adipocytes (8). Understanding the cross talk between immune cells and adipocytes in the 
context of obesity is essential to define the pathological bases of metabolic diseases such as insulin 
resistance and type 2 diabetes.  
In last decade, oncostatin M (OSM) has appeared as a relevant factor in the pathophysiology 
of obesity and other diseases (9). Indeed, it has been reported that OSM is an important target for 
breast cancer and inflammatory bowel disease (10, 11).  In support of this notion, OSM 
immunoneutralization in animal models can improve these diseases (10, 11). OSM is a gp130 
cytokine with its own specific receptor, OSMR, that heterodimerizes with gp130 and mediates the 
majority of OSM actions (12). OSM shares substantial sequence identity with leukemia inhibitory 
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factor (LIF) (13) and can modulate a variety of biological processes, such as liver development and 
regeneration (14, 15), hepatic insulin resistance and steatosis (16), inflammation (17), and 
cardiomyocyte dedifferentiation and remodeling (18). OSM has been also reported to promote bone 
formation and to inhibit adipogenesis (19-24). 
Previously, we demonstrated that OSM was overproduced in WAT under obese conditions in 
mice and humans (25). In addition, we observed that OSM treatment inhibited adipogenesis in brown 
adipose tissue (BAT) and browning of WAT  in vitro and in vivo using murine models (26). In this 
study, we aimed to decipher the role of OSM in promoting the inflammatory state that underlies the 
altered glucose homeostasis in obesity. We also addressed the therapeutic potential of  OSM 
immunoneutralization to prevent an impairment in glucose homeostasis in vivo. 
 
Materials and Methods 
Human subject characteristics 
45 patients with severe obesity (body mass index > 35 kg/m2 and comorbidities including 
type 2 diabetes, hypertension or dyslipemia) were included in our cohort (Table 1). Patients were 
stratified into two groups according to their fasting glycemia: normoglycemic patients (glucose<100 
mg/dL) (n=26) and hyperglycemic patients (glucose >100 mg/dL) (n=19). All patients were evaluated 
by the same endocrinology specialist (S.P) according to criteria for bariatric surgery formulated in 
Spanish Position Statement between Obesity, Endocrinology, Diabetes and Surgery Societies (27). 
Demographic and clinical data, including age, history of diabetes, and hypertension were recorded 
for all subjects. 
Serum samples and tissues  
Serum samples from the study subjects were collected after a 12h fasting period. All samples 
were stored at -80ºC in the Biobank of the Health Sciences Research Institute Germans Trias i Pujol 
Foundation. 
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Twenty-one of these 45 patients with obesity (10 normoglycemics (9 females/1 male) and 11 
hyperglycemics (6 females/5 males) were selected to analyze subcutaneous and visceral WAT 
(sWAT and vWAT, respectively) samples from the abdominal region. These 21 patients were chosen 
according to the following criteria: a) available sWAT and/or vWAT biopsis to isolate the required 
amount of high-quality RNA, and b) clinical history with at least body weight and blood glucose data 
available (see Flow chart in Supplementary Figure S1 (28)). WAT samples from patients with obesity 
were collected during bariatric surgery and immediately frozen at -80ºC.  
The Institutional Ethics Committee, in accordance with the Declaration of Helsinki, approved 
the study (PI16-025). All participants gave their written informed consent before collecting clinical 
data and samples. 
Human serological analysis 
Glucose and insulin levels, and lipid profiles (total cholesterol, HDL and LDL cholesterol, 
and triglycerides) were measured in the certified core clinical laboratory at the hospital. Leptin and 
HMW-adiponectin levels were measured by specific ELISA kits (EZHL-80SK, Merck-Millipore and 
RYD-DHWAD0, R&D Systems, respectively). The homeostatic model assessment of insulin 
resistance (HOMA-IR) was calculated with the following formula:  
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =
[𝐺𝑙𝑢𝑐𝑜𝑠𝑒
𝑚𝑔
𝑑𝐿
] ∗ [𝐼𝑛𝑠𝑢𝑙𝑖𝑛
m.u.int
𝑑𝐿
]
405
 
Human SGBS cell differentiation and OSM treatment  
Simpson Golabi Behmel Syndrome (SGBS) human preadipocytes (29) were differentiated to 
adipose cells as reported previously (30). Briefly, pre-adipocytes were maintained with DMEM/F12 
supplemented with 10% heat inactivated FBS, 32 µM biotin and 16 µM pantothenic acid. To induce 
their differentiation, cells were incubated with DMEM/F12 supplemented with 32 µM biotin, 16 µM 
pantothenic acid, 25nM dexamethasone, 500 µM IBMX, 2 µM rosiglitazone, 10 µg/mL transferrin, 
20 mM insulin, 100 nM cortisol and 0.2 nM T3 for 7 days and incubated with DMEM/F12 
supplemented with 32 µM biotin, 16 µM panthotenic acid, 10 µg/mL transferrin, 20 µM insulin, 100 
nM cortisol and 0.2 nM T3 for 7 additional days or until they reached more than 90% of 
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differentiation. Where indicated, cells were treated with 1 mM cAMP (Sigma-Aldrich) and 1nM 
OSM (R&D systems; reference 295-OM-CF) for 6 and 24h or with 1 µM CL316.243 (Cayman 
Chemicals) for 24h for acute response. Cells were treated with 1 nM OSM (~22ng/ml) during all 
differentiation processes for chronic response studies.  
Gene expression analyses 
Total RNA was extracted from whole adipose tissue or cells using a column-affinity based 
methodology (NucleoSpin RNA II; Macherey-Nagel, Duren, Germany). 500 ng of total RNA were 
retrotranscribed into cDNA using random hexamer primers and Multiscribe reverse transcriptase 
(TaqMan reverse transcription reagents, Thermo Fisher Scientific), following the manufacturer’s 
instructions. Platinum Quantitative PCR SuperMix-UDG with ROX reagent (Themo Fisher) was 
used as master mix reagent and expression levels of each gene of interest were assessed with the 
specific TaqMan probes (Thermo Fisher) (Supplementary Table S1 (28)). Gene expression was 
calculated by ΔΔCt method and expressed in arbitrary units. 
Animal studies 
Immunoneutralization study 
Animals used in this study included male C57BL/6J mice fed a high-fat diet (HFD; 60% kcal 
from fat, Research Diets Inc, D12492). A group of male mice fed a low-fat diet (10% kcal from fat, 
Research Diets Inc, D12450B) was used as a diet control (n= 6). HFD feeding began at 8-weeks of 
age and extended for a 9-week period. After 7 weeks of HFD feeding, animals were randomized into 
two groups: a) mice receiving intraperitoneal injections twice a week for a total dose of 250 µg anti-
OSM antibody (PA547022; Thermo Fisher Scientific, United States) over 2 weeks (n= 6); b) mice 
receiving intraperitoneal injections twice a week for a total dose of 250 µg IgG non-specific antibody 
(PA547309; Thermo Fisher Scientific, United States) over 2 weeks (n= 6) (Supplementary Figure S2 
(28)). Antibody dosing was based on a previous study performed by Lapeire et al (10). 
Tissues were collected for total RNA analysis. All experimental procedures were approved 
by the Institutional Animal Care and Use Committee of the University of Barcelona following the 
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principles outlined in the Declaration of Helsinki for animal experimental investigation. 
Glucose and insulin tolerance tests 
For glucose tolerance test (GTT), mice were first fasted for 12 h. Then, they were injected 
intraperitoneally with glucose (2 g/Kg body weight) and blood glucose was measured at 0, 30, 60, 90 
and 120 min. For insulin tolerance tests (ITT), mice were fasted for 5 h and then blood glucose was 
measured at 0, 30, 60, 90 and 120 min following an intraperitoneal injection of insulin (0.85 U/Kg of 
body weight). Glucose levels were measured in blood using an ELITE glucometer (Bayer, Spain). 
Rodent serological analysis  
Blood was obtained by cardiac puncture and centrifuged at 2000 rpm for 10 minutes at 4 ºC 
to obtain serum. Total cholesterol and triglyceride levels were quantified by using commercial kits 
based on the Trinder method (FAR Diagnostics, Verona, Italy). Non-esterified fatty acids (NEFA) 
were measured in serum samples with the NEFA-C kit (Wako Chemicals, Neuss, Germany). Insulin 
levels were determined with an ultra-sensitive mouse insulin ELISA kit (Crystal Chem, Zaandam, 
The Netherlands). 
Osmr FKO mice 
Male adipocyte-specific Osmr knockout (OsmrFKO; n=6) and littermate floxed control 
(Osmrfl/fl; n=6) mice on a C57BL/6J background, generated as described previously (31, 32), were 
fed a HFD (45% calories from fat; Research Diets; D12451) for 20 weeks, beginning at 6 weeks of 
age. Body weights were obtained weekly. After 20 weeks of feeding, blood glucose levels were 
obtained after a 4-hour fast, mice euthanized, and inguinal white adipose tissue (iWAT) collected for 
gene expression analyses. 
Western blotting 
50  mg o f  f rozen white adipose tissue were homogenized in 15 0u l  o f  a  buffer con ta in in g  
50mM TrisHCl pH 7.4, 150 mM NaCl, 1.5mM MgCl2, 1 mM EDTA, 1% v/v Triton X-100, protease 
inhibitor cocktail (Roche) and phosphatase inhibitors (2mM sodium orthovanadate, 1mM sodium 
pyrophosphate, 10mM sodium fluoride). Lysates were centrifuged at 16,000 g at 4°C for 10 min. 
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Protein concentration was measured using the bicinchoninic acid (BCA) protein assay as specified 
by the manufacturer (Pierce, Thermo Fisher Scientific, Rockford, IL). 30µg of protein of each sample 
(n=3) were resolved by SDS-polyacrylamide 12% gels and transferred onto PVDF membranes (GE 
Healthcare, Chicago, IL). Membranes were blocked for 1 h at room temperature (RT) in PBS 1x with 
0.1% Tween 20 and 5% skimmed milk. Primary antibody rabbit anti-p44/42 MAPK (Erk1/2) (9102; 
Cell Signaling Technology, Danvers, MA) 1/1000 and rabbit anti-Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (9101; Cell Signaling Technology) 1/1000 were incubated overnight at 4 ºC in 
PBS1x–0.1% Tween20-3% milk. After incubation with HRP-labelled secondary antibodies for 1h at 
RT in PBS1x–0.1% Tween20-3% milk, membranes were developed with the ECL system (Millipore-
Merck, Burlington, MA) and chemiluminescence was measured using the LAS-3000 Imager 
(Fujifilm, Tokyo, Japan). 
Histological analysis 
Samples from WAT and BAT were fixed for 24 hours in 4% paraformaldehyde and embedded 
in paraffin. Paraffin blocks were cut into 5 μM sections and stained 
with hematoxylin and eosin (H&E) or used for immunohistofluorescence (IHF) staining. For IHF, 
rehydrated tissue sections were blocked with 3% BSA for 1h at room temperature. Preparations 
were then incubated with rat anti-mouse F4/80 (ab6640, Abcam) or goat anti-mouse CD206 (sc-
34577, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies at a concentration of 
10 μg·mL-1followed by AlexaFluor 488-conjugated anti-rat or anti-goat IgG secondary antibodies 
(Thermo Fisher Scientific). Immunofluorescence signals were visualized under a fluorescence 
microscope (Leica). All signal counting procedures were performed by an observer blinded to the 
identity of samples. 
Statistical analysis 
Data are presented as mean ± SD or SEM (for humans and mice, respectively). Correlation 
analysis was implemented in SPSS Statistics (IBM). Normality of datasets was assessed with a 
Kolmogorov-Smirnoff test. Statistical significance was determined using a two-tailed t-test, a Mann-
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Whitney U-test for non-parametric data, or a one-way ANOVA with Tukey’s post-hoc test for more 
than two groups. p<0.05 was established as the statistical significance threshold for all analyses. 
 
Results 
OSM expression is elevated in sWAT and vWAT from hyperglycemic patients with obesity and 
correlates with Glut4, Ccl2, Nos2 and Pai1 mRNA levels 
We previously demonstrated that OSM expression is elevated in conditions of severe obesity 
(25). However, the relationship between adipose tissue OSM expression and glycemia in patients 
with obesity has not been explored. Here, in an independent cohort of patients with severe obesity 
(Table 1), we analyzed whether OSM levels were correlated with altered glucose homeostasis in 
obesity, by comparing WAT OSM expression levels in hyperglycemic  and normoglycemic patients. 
We observed that the mRNA levels of OSM were increased in sWAT and vWAT from hyperglycemic 
patients when compared to those in normoglycemic patients (Figure 1A). We also found a decrease 
in Glut4 mRNA levels in WAT from patients with hyperglycemia (Figure 1B), and an inverse 
correlation with OSM mRNA levels (Figure 1C). Moreover, OSM expression correlated with 
transcript levels of some inflammatory molecules, such as Ccl2, Tnfα, and Col6 (a marker of fibrosis) 
(Figure 1D-F), although no correlation with Nos2 and Pai1 expression was observed (Figures 1G and 
1H). 
In addition, we found direct positive correlations between OSM expression and insulin levels 
or HOMA-IR in sWAT but not in vWAT, and no correlation with body weight (Figure 2), suggesting 
that OSM expression in sWAT is associated with reduced insulin sensitivity in obesity. After 
performing a linear regression analysis with all the clinical parameters and adjusting by sex and age, 
correlations between OSM expression and insulin or HOMA-IR were not maintained. However, body 
weight was as an independent predictor of OSM gene expression (Supplementary Table S2 (28)).  
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OSM inhibits differentiation and induces inflammatory markers in human adipocytes 
The effects of OSM on human adipogenesis have not been previously addressed. Therefore, 
human cells were treated with human recombinant OSM during differentiation (chronic exposure) or 
after cells were completely differentiated into mature adipocytes (acute exposure). As shown in 
Figure 3A, OSM treatment caused complete inhibition of adipogenesis. OSMRβ was expressed in 
both preadipocytes and mature adipocytes, with higher levels in preadipocytes (Figure 3B). In 
addition, acute treatment of mature adipocytes with OSM produced significant increases in Ccl2, 
Pai1 and Il-6 expression, and a significant decrease in Glut4 at 24 hours (Figure 3C). Conversely, 
Col6 and Adipoq gene expression levels were not significantly regulated by OSM treatment (Figure 
3D). 
 
OsmrFKO mice exhibit enhanced sWAT Glut4 mRNA levels compared to Osmrfl/fl controls 
Since OSM was elevated in the sWAT of patients with obesity and insulin resistance, and 
considering that OSM treatment decreased Glut4 gene expression and increased inflammatory gene 
expression in human adipocytes, we next sought to evaluate the in vivo effects of diminished 
adipocyte OSM signaling on these parameters. To accomplish this, we used HFD-fed OsmrFKO and 
Osmrfl/fl control mice. Importantly, body weights did not significantly differ between genotypes 
(Figure 4A). We did observe a significant increase in sWAT Glut4 mRNA levels in OsmrFKO mice 
compared to floxed control mice (Figure 4B), but transcript levels of inflammatory markers Ccl2, 
Nos2 and Pai1 remained unchanged (Figure 4C-E). 
 
OSM immunoneutralization reduces Ccl2 expression in white and brown adipose tissue and 
normalizes glucose levels in diet-induced obese mice 
We aimed to evaluate the effect of systemic OSM inhibition on WAT and glucose 
homeostasis. To achieve this goal, we administered an anti-OSM antibody for 2 weeks to mice that 
had been previously fed a HFD for 7 weeks. Lower levels of phospho p44/42 mitogen-activated 
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protein kinases (MAPKs) (p-ERK1/2), a signaling kinase activated by OSM, were observed in mice 
treated with anti-OSM (Supplementary Figure S3 (28)), demonstrating the efficiency of the treatment 
of mice with the anti-OSM antibody in preventing the activation of OSM-induced signaling pathway. 
In addition, we measured OSM and OSMR gene expression and other pro and anti-inflammatory 
markers (Tnf, Nos2, and Il10) and F4/80 levels by immunostaning in the eWAT of the 3 groups of 
mice (low-fat control diet, HFD anti-IgG and HFD anti-OSM antibody). Significant increases in Osm, 
Tnf and Il10 mRNA levels were observed in the HFD anti-IgG group, in addition to more F4/80 
positive cells, while these increases were not significant in mice treated with anti-OSM antibody.  
These results demonstrate the partial benefit of anti-OSM antibody injection, which was sufficient to 
ameliorate general inflammatory response (Supplementary Figure S4 (28)). 
Mice treated with the anti-OSM antibody exhibited lower glucose levels compared to the anti-
IgG control group, in a similar extent to those present in mice fed a low-fat control diet (Figure 5A). 
Insulin levels showed a tendency to be higher in the anti-OSM antibody group compared to anti-IgG 
group and were significantly different than those observed in the low-fat control diet group (Figure 
5B). Consistent with our in vitro data in human adipocytes, we observed that administration of an 
anti-OSM neutralizing antibody lowered Ccl2 gene expression in eWAT and BAT of HFD-fed mice 
when compared to HFD-fed mice given the anti-IgG control antibody (Figures 5D and E). There were 
no differences in Ccl2 expression in iWAT (Figure 5F). PAI1 expression increased in BAT with HFD 
and was normalized after OSM immunonetralization (Figure 5G), and no changes were found in 
WAT (Figures 5 H and I). Moreover, we did not observe changes in Glut4 mRNA levels in iWAT 
from the 3 groups of study (Figure 5C). As expected, compared to mice fed a low-fat control diet, 
HFD-fed mice exhibited impaired glucose homeostasis (Suplemmentary Figure S5A) in close 
association with the development of obesity. Despite changes in basal glucose levels, treatment with 
anti-OSM antibody for two weeks did not induce any significant changes in glucose tolerance or 
insulin sensitivity compared with mice treated with anti-IgG antibody (Suplemmentary Figure S5A-
B). Similarly, no differences in body weight or food intake were observed between IgG or anti-OSM 
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antibody-treated mice (Supplementary Figure S5C-D (28)). WAT and BAT weights were similar in 
both groups of HFD-fed mice, independently of treatment (Supplementary Figures S6A-C (28)). 
Moreover, no differences in Pparγ expression were observed in WAT and BAT from either group on 
HFD (Supplementary Figures S6D-F (28)), suggesting that adipogenesis was not affected by the 
neutralizing antibody. Consistent with this, adipocyte size in iWAT and eWAT depots was not 
affected by the treatments (data not shown). 
 
Discussion 
In this study, we report for the first time that OSM is differentially expressed in adipose tissue 
from hyperglycemic patients with obesity when compared to normoglycemic patients with a similar 
degree of obesity. In addition, we demonstrate that OSM inhibits human adipogenesis, reduces Glut4 
expression, and induces an inflammatory state in human adipocytes. The inhibitory effect of OSM on 
adipocyte differentiation has been previously reported in different conditions (19-24). Here, we link 
the capacity of OSM to impair adipogenesis with its potential role to promote an inflammatory state, 
contribuiting to the development of insulin resistance in obesity. Consistent with these observations, 
our data in animal models also demonstrate that  OsmrFKO mice show higher levels of Glut4 compared 
to floxed controls, and that OSM immunoneutralization reduces inflammatory markers and decreases 
basal glucose levels in obese mice.  
In the last decade, the enigmatic concept of “healthy obesity” has emerged in the field of 
metabolism (33). Whether healthy obesity is only a transient state in the progression towards 
metabolic disease is controversial and still a subject of intense debate. But, it is clear that some 
patients maintain normal glucose homeostasis in presence of obesity (34). Metabolically healthy 
patients with obesity are characterized by the absence of metabolic complications such as 
dyslipidemia, insulin resistance, and unfavorable inflammatory profiles (35). Whereas dietary 
composition and physical activity are factors that have been related to metabolic health in patients 
with obesity, numerous studies have provided evidence implicating chronic inflammation, 
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particularly in adipose tissue, as a key factor in determining an unfavorable metabolic outcome in 
patients. Indeed, higher levels of pro-inflammatory cytokines, including C-reactive protein, Il-6, Pai1 
or Tnfα have been reported in unhealthy obesity compared with healthy obesity (36, 37).  
In this regard, OSM, a cytokine from the Il-6 family, is produced by adipose tissue and highly 
expressed in WAT of mouse models of diet-induced and genetic obesity, as well as in humans with 
obesity (25). Our data showing that increased expression of OSM in WAT correlates with markers of 
metabolic disease, including decreased Glut4 expression, hyperglycemia, hypersulinemia, and 
increased HOMA-IR in patients with obesity, suggests that OSM is a marker of unhealthy obesity.  
The correlation of OSM levels in sWAT with glycemia, but not with body weight, in patients 
may seem somewhat paradoxical given the finding that OSM negatively acts on precursor cells to 
inhibit adipocyte differentiation in vitro. A regulatory role of OSM on adipose tissue mass is 
supported by studies in mice lacking whole-body OSM receptor (OSMRβ), which show increased fat 
mass (38, 39). However, in humans, the causal factors underlying fat accretion in obesity are yet to 
be fully determined, and genetic or lifestyle factors (hypercaloric diets, sedentarism) may override 
the protective effect of OSM. On the other hand, the lack of any effect on body weight and adipose 
tissue mass in mice treated with an anti-OSM neutralizing antibody could be explained by: a) the 
short period of treatment (only two weeks), which was likely not sufficient to observe the effects of 
impaired adipocyte differentiation on WAT mass ,  or b) the dosage used. 
A major finding of our study is the observation of direct correlations between OSM and 
inflammatory markers such as the monocyte chemoattractant, Ccl2, in WAT of patients. These results 
are in accordance with our previous data and with studies by other researchers that reported a pro-
inflammatory role for OSM (10, 11, 25). Moreover, the effect of OSM in inducing these inflammatory 
genes in human adipocytes strongly suggests a potential role for OSM in adipose tissue inflammation 
in patients. 
In addition, OSM downregulates Glut4 in WAT as demonstrated by the decreased WAT Glut4 
expression in patients with obesity and hyperglycemia, the inverse correlation with OSM expression, 
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and the response to direct OSM exposure in human adipocytes. These results are suported by the 
elevation of sWAT Glut4 expression in OsmrFKO mice compared to floxed controls. These data 
suggest a potential contribution of this cytokine to impaired insulin sensitivity. This elevation in Glut4 
is unique to sWAT; as no differences were previously observed in vWAT Glut4 expression in 
OsmrFKO mice (31). This depot-specific expression pattern provides additional support for the 
possible protective role of sWAT, especially considering the increased vWAT inflammation observed 
in OsmrFKO mice on both HFD and chow diets (31, 32). 
Work by Elks et al using C57BL/6J mice demonstrated that OSM is primarily expressed in 
adipose tissue immune cells, and that OSMR is also expressed in cellular components of the adipose 
tissue immune system (32). Interestingly, however, Osmr expression increases only in adipocytes 
from HFD-fed mice (32). Further work using the adipocyte-specific OsmrFKO mouse model showed 
significant increases in adipose tissue Osm expression in OsmrFKO mice compared to Osmrfl/fl controls, 
along with increased adipose tissue inflammation. These findings suggest that since OSM could not 
bind OSMR on OsmrFKO adipocytes, it was instead acting on other cell types within adipose tissue to 
promote inflammation and insulin resistance (31, 32).  
Taking into account studies indicating that adipocyte OSMRβ signaling is important for 
adipose tissue homeostasis (31, 32), we examined the effects of OSM immunoneutralization on 
metabolic parameters in diet-induced obese mice. Regarding the inflammatory state, we observed a 
significant increase in OSM, TNF and Il10 mRNA levels in HFD-fed mice treated with IgG 
antibody, while this increase was not significant in HFD-fed mice treated with anti-OSM antibody 
compared to mice fed low-fat diet. The elevated levels of Il10 in HFD-fed mice might be due to a 
compensatory mechanism against the increasing inflammatory process. 
Moreover, anti-OSM treatment reduced the HFD-induced increase of Ccl2 expression in 
vWAT and BAT, and also decreased Pai1 expression in BAT. Further, glucose levels were 
normalized in HFD-fed mice after the OSM immunonetralization, although treatment with the anti-
OSM antibody did not significantly alter whole body glucose tolerance or systemic insulin sensitivity. 
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Since we did not observe changes in Glut4 expression, the mechanisms by which OSM neutralization 
normalized glucose levels in HFD-induced obese mice are still unclear. They may involve a reduction 
in the local adipose tissue inflammatory state and immune cell infiltration, as evidenced by reduction 
in transcript levels of chemoattractant and proinflammatory molecules, with a consequent 
improvement in adipocyte insulin sensitivity. However, the contribution of other tissues in response 
to treatment with this antibody cannot be disregarded. For example, the observed increase in insulin 
levels in anti-OSM treated mice could suggest direct effects on pancreatic β-cells. Moreover, a 
decrease in hepatic gluconeogenesis is also compatible with our observations. In this regard, OSM 
released by Kupffer cells in response to prostaglandin E2 has been shown to inhibit hepatic insulin 
signaling and to promote abnormal lipid accumulation (16). 
Similar to studies by Komori et al. (38-40), we are confident that OSM is secreted from non-
adipocyte cells in white adipose tissue under obese conditions in mice and humans, and that the 
expression of the OSM receptor, OSMRβ, is elevated in adipose tissue in conditions of obesity. 
However, a clear divergence between our observations and those reported in by Komori includes the 
primary function of OSM signaling in adipose tissue. Our results demonstrate that OSM has 
proinflammatory roles on adipocytes, including induction of Ccl2 and Pai-1, and that levels of OSM 
in adipose tissue inversely correlated with glucose homeostasis parameters. Our observations 
supporting that elevated OSM levels in adipose tissue have negative effects, as part of an overall pro-
inflammatory enhancement, are consistent with several studies by other laboratories. Lapeire et al. 
demonstrated recently that, of all the cytokines secreted by mammary adipose tissue, OSM is the 
most relevant secreted factor in stimulating breast cancer progression (10). Also, a study by Albiero 
et al. suggests that OSM antagonism is a strategy to restore bone marrow function in diabetes to 
combat the effects of elevated OSM levels produced in bone marrow macrophages in diabetics (41). 
We and others observed proinflammatory actions of OSM in adipocytes in mouse and human 
adipocytes (25, 42, 43). The fact that OSM is a strong inhibitor of adipogenesis (19-24) is consistent 
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with our proposal of OSM as a damaging factor on glucose homeostasis, as factors that limit fat cell 
expansion are commonly associated with metabolic dysfunction (7). 
It is also important to point out that, for their studies in vivo, Komori et al. used a dose of  
recombinant OSM to treat mice (12.5 ng/g body weight, administered twice daily) (40) which is at 
least three to four orders of magnitude above the highest reported levels of circulating OSM in 
humans (42). A potential explanation for the differing conclusions could be related to the use of 
whole-body, constitutive, Osmr KO mice by Komori et al.  Osm has well-known critical roles in liver 
development and hematopoiesis (14-18) and is expressed in many tissues during both embryonic 
development and adulthood in mice (42). OSMR-null mice had mature-onset obesity and insulin 
resistance (38), but this may be the result of multiple damaging events on early development, 
differentiation and cell programming beyond the actual role of OSM in adipose tissue when obesity 
develops in adulthood. 
Since immunotherapy is being used to treat several inflammatory diseases (44), the practical 
implication of this study is to open the window for potential approaches targeting immunoregulation 
of adipose tissue in obesity to prevent and treat insulin resistance. 
Regardless, our study presents some limitations, including the relatively low number of 
human adipose tissue samples and the lack of circulating OSM levels in these patients. Moreover, a 
polyclonal goat IgG might be immunogenic in mice and could act by neutralizing antibody responses 
over a two-week treatment period leading to a lack of effect due to poor drug pharmacokinetics. 
Further studies evaluating the effect of antibody treatment at earlier timepoints would be necessary 
to decipher whether OSM immunoneutralization could be a potential strategy to treat insulin 
resistance.  
In conclusion, OSM is elevated in adipose tissue from patients with obesity and impaired 
glucose metabolism, and inversely correlates with Glut4 expression in this tissue. Moreover, OSM 
promotes an inflammatory state during obesity, likely in part through the inhibition of adipogenesis, 
a direct reduction of the mRNA levels of Glut4 and induction of the expression of inflammatory 
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markers. Finally, OsmrFKO mice showed elevated levels of Glut4, and OSM immunoneutralization 
reduced adipose tissue Ccl2 and Pai1 expression in obese mice, and normalized glucose levels, 
demonstrating the negative action of OSM on glucose homeostasis. Further studies will be necessary 
to decipher whether blockage of OSM signaling can be a therapeutic target in preventing the 
development of T2D. 
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Figure legends 
Figure 1: OSM expression is significantly elevated in sWAT and vWAT from hyperglycemic 
patients and correlates with Glut4, Ccl2, Tnfα and Col6 gene expression.  
Gene expression analysis of OSM (A) and Glut4 (B) in sWAT and vWAT from normoglycemic 
patients with obesity and hyperglycemic patients with obesity. Correlations between OSM expression 
and Glut4 (C), Ccl2 (D), Tnfα (E), Col6 (F), Nos2 (G) and Pai1 (H) gene expression.  Expression 
levels are normalized to the reference gene Ppia. Data are presented as means ± s.e.m. (n= 21 samples, 
analytical assays performed in triplicate) * p<0.05 vs. normoglycemic obesity group.  
 
Figure 2: OSM gene expression in sWAT but not in vWAT correlates with circulating insulin 
levels and HOMA-IR.  
Correlations between OSM expression in sWAT and vWAT and insulin levels (A (n=14), D (n=15)), 
HOMA-IR (B (n=12), E (n=15)) and body weight (C (n=21), F (n=16)). Expression levels are 
normalized to the reference gene Ppia. Data are presented in arbitrary units as means ± s.e.m. 
(analytical assays performed in triplicate).  
 
Figure 3: OSM inhibits human adipogenesis and induces a pro-inflammatory gene expression 
profile in mature human adipocytes.  
A) Representative optical microscopy images from human preadipocytes treated with 1 nM OSM 
since day 1 of differentiation. *p<0.05 relative to control. B) Relative mRNA levels of OSMRβ in 
preadipocytes and mature adipocytes. C) Relative mRNA levels of Ccl2, Pai1, Il-6 and Glut4 in 
human mature adipocytes treated with 1nM OSM for 6 or 24 h. D) Relative mRNA levels of Col6 
and Adipoq. Expression levels are normalized to the reference gene Ppia. The bars represent means 
± s.e.m. Each figure represents an experiment independently performed 3 times with 3 replicates per 
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sample. The mass unit concentration of 1 nM recombinant human OSM is ~22 ng/ml. 
 
Figure 4: OsmrFKO mice exhibit elevated Glut4 mRNA levels, but no changes in inflammatory 
markers, compared to floxed controls 
Body weight of OsmrFKO mice and control littermates fed a HFD (A). Relative mRNA levels of Glut4 
(B), Nos2 (C), Ccl2 (D) and Pai1 (E) in  iWAT from HFD-fed OsmrFKO mice and Osmrfl/fl controls. 
Data are presented in arbitrary units as means ± s.e.m. (n=6 mice per group and analytical assays 
performed in triplicate). Expression levels are normalized to the reference gene Ppia. * p<0.05 
OsmrFKO vs. Osmrfl/fl control mice.  
 
Figure 5: OSM immunoneutralization decreases Ccl2 expression in WAT and BAT and 
normalizes glucose levels. 
Glucose (A) and insulin (B) levels in random fed animals. Glut4 mRNA levels in iWAT (C). Relative 
mRNA levels of Ccl2 (D, E, F) and Pai1 (G, H, I) in WAT and BAT. The 3 groups correspond to: 
mice fed low fat control diet (control diet), mice fed a HFD and treated with unspecific IgG (HFD 
control), and mice fed a HFD and treated with anti-OSM Ab (HFD Ab). Data are presented in 
arbitrary units as means ± s.e.m. (n=6 mice per group and analytical assays performed in triplicate) * 
p<0.05 vs control diet. 
 
Table 1. Anthropometric and metabolic parameters of human subjects. 
Data are shown as mean ± (SD). LDL-Cho. HbA1c, glycated hemoglobin; HOMA-IR, Homeostatic 
model Assessment-insulin resistance; Low-density lipoprotein; HDL-Cho, High-density 
lipoprotein.*p value< 0.05 
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Table 1.- Anthropometric and metabolic parameters of human subjects. 
 
Normo 
(n=26) 
Hyper  
  (n=19) 
   
 Mean ± SD Mean ± SD 
Age (years) 48±11 52±10 
Sex (Female/Male) 20/6 14/5 
History of T2D no 7 T2D/12 pre-T2D 
History of Hypertension (yes/not) 9/17 7/12 
Weight (kg) 108 ± 19 117 ± 39 
Height (cm) 163 ± 0.1 161 ± 0.3 
Waist circumference (cm) 131 ± 11.2 146 ± 37.3* 
Body mass index (kg/m2) 41 ± 8.8 43 ± 10.8 
Glucose (mg/dL) 91 ± 5 152 ± 46* 
Insulin (m.u.int/L)  6.3 ± 3.4 7.7 ± 4.0 
HbA1c (%) 5.3 ± 0.4 5.8 ± 0.2* 
HOMA-IR (%) 1.4 ± 0.8 2.5 ± 1.3* 
Triglyceride (mg/dL) 135 ± 41 161 ± 77 
LDL-cholesterol (mg/dL) 95 ± 27 119 ± 23* 
HDL-cholesterol (mg/dL) 41 ± 11 42 ± 10 
Total cholesterol (mg/dL) 163 ± 34 191 ± 30* 
HMW-adiponectin (ng/mL) 3016 ± 1849 2884 ± 1835 
Leptin (ng/mL) 54.9 ± 25.1 42.8 ± 13.5 
 
Data are shown as mean ± (SD). T2D, type 2 diabetes. HbA1c, glycated hemoglobin; HOMA-IR, 
Homeostatic model assessment-insulin resistance; Low-density lipoprotein; HDL-Cho, High-density 
lipoprotein; HMW-adiponectin, high molecular weight adiponectin.*p value< 0.05 
Insulin (n= 20 normo and 10 hyper); HbA1c (n= 22 normo and 20 hyper); HOMA-IR (n= 20 normo 
and 10 hyper); Triglycerides (n= 25 normo and 11 hyper); LDL-cholesterol (n= 24 normo and 12 
hyper); HDL-cholesterol (n= 24 normo and 12 hyper); Total cholesterol (n= 25 normo and 12 hyper); 
HMW-adiponectin (n= 13 normo and 8 hyper); Leptin (n= 13 normo and 8 hyper). 
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